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Summary
The autosomal recessive disorder primary congenital
glaucoma (PCG) is caused by unknown developmental
defect(s) of the trabecular meshwork and anterior cham-
ber angle of the eye. Homozygosity mapping with a
DNA pooling strategy in three large consanguineous Sa-
udi PCG families identified the GLC3A locus on chro-
mosome 2p21 in a region tightly linked to PCG in an-
other population. Formal linkage analysis in 25 Saudi
PCG families confirmed both significant linkage to poly-
morphic markers in this region and incomplete pene-
trance, but it showed no evidence of genetic heteroge-
neity. For these 25 families, the maximum combined
two-point LOD score was 15.76 at a recombination
fraction of .021, with the polymorphic markerD2S177.
Both haplotype analysis and homozygosity mapping in
these families localized GLC3A to a 5-cM critical in-
terval delineated by markers D2S2186 and D2S1356.
Sequence analysis of the coding exons for cytochrome
P4501B1 (CYP1B1) in these 25 families revealed three
distinctive mutations that segregate with the phenotype
in 24 families. Additional clinical and molecular data
on some mildly affected relatives showed variable ex-
pressivity of PCG in this population. These results
should stimulate a study of the genetic and environ-
mental events that modify the effects of CYP1B1 mu-
tations in ocular development. Furthermore, the small
number of PCG mutations identified in this Saudi pop-
ulation makes both neonatal and population screening
attractive public health measures.
Received September 17, 1997; accepted for publication December
2, 1997; electronically published February 13, 1998.
Address for correspondence and reprints: Dr. James R. Lupski, De-
partment of Molecular and Human Genetics, Baylor College of Med-
icine, One Baylor Plaza, Houston, TX 77030. E-mail:
jlupski@bcm.tmc.edu
∗ Present affiliation: Beirut Eye Specialist Center, Rizk Hospital,
Beirut.
† Present affiliation: Department of Pediatric Ophthalmology, Al-
berta Children’s Hospital, Calgary.
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6202-0017$02.00
Introduction
The glaucomas are a heterogeneous group of insidious
disorders that combine elevated intraocular pressure
(IOP) and optic nerve damage that culminate in blind-
ness (Allingham 1994). The most common forms, open-
angle glaucomas, have onset in midadulthood and re-
lentless slow progression, unless appropriate medical
and/or surgical therapies are instituted. The juvenile and
infantile glaucomas are more severe clinically and more
difficult to manage. Autosomal dominant juvenile-onset
open-angle glaucoma (JOAG) (MIM 137750 [http://
www3.ncbi.nlm.nih.gov:80/htbin-post/Omim/dispmim?
137750]) (McKusick 1994) has a characteristic onset in
the 2d or 3d decade, high IOP, poor responsiveness to
medical therapy, and frequent dependence on filtering
surgery to control both pressure and the attendant optic
neuropathy. Recently, several investigators have estab-
lished linkage for a locus,GLC1A, for JOAG tomarkers
on chromosome 1 (Sheffield et al. 1993; Richards et al.
1994; Wiggs et al. 1994; Morissette et al. 1995) and
have identified mutations in a gene, TIGR, encoding a
trabecular meshwork protein (Stone et al. 1997).
Primary congenital glaucoma (PCG) (MIM 231300
[http://www3.ncbi.nlm.nih.gov:80/htbin-post/Omim/
dispmim?231300]) (McKusick 1994) is a clinical and
genetic entity clearly distinct from the juvenile forms
(Lichter 1994; Anderson et al. 1996). This devastating
autosomal recessive disorder is caused by unknown de-
velopmental defect(s) of the trabecular meshwork and
anterior chamber angle and manifests in the neonatal or
infantile period (Franc¸ois 1980; Hoskins et al. 1984).
PCG occurs when the developmental anomalies of the
angle prevent adequate drainage of aqueous humor, so
that the IOP is elevated (deLuise and Anderson 1983).
The coats of the infantile eye are sufficiently elastic that
they stretch with this elevated pressure and yield an en-
larged globe (buphthalmos).
Although PCG is the most common form of glaucoma
in infancy, nothing certain is known about its specific
pathogenesis, despite studies of various animal models
(Hanna et al. 1962; Gelatt et al. 1976; deLuise and An-
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derson 1983; Dickens and Hoskins 1989; Buyse 1990).
However, there is consensus about its classic clinical
characteristics (Franc¸ois 1980): (1) elevated IOP; (2) en-
largement of the globe, particularly the anterior segment;
(3) edema and opacification of the cornea, with rupture
of Descemet’s membrane; (4) thinning of the anterior
sclera and atrophy of the iris; (5) anomalously deep an-
terior chamber; (6) structurally normal posterior seg-
ment, except for progressive optic atrophy; and (7) pho-
tophobia, blepharospasm, and excessive tearing
(hyperlacrimation). Differentiation of affected from un-
affected siblings is not difficult, especially in the Saudi
Arabian population, in which the disorder appears to
be more severe, and both relative delay in parental rec-
ognition and slow access to medical care are frequent
events. Nevertheless, PCG is likely to be genetically het-
erogeneous, on the basis of current clinical and genetic
data (Lichter 1994; Sarfarazi et al. 1995).
Recently, a putative PCG locus, GLC3A, was linked
to markers on the short arm of chromosome 2 in 11
Turkish families (Sarfarazi et al. 1995). Six other Turkish
families did not show linkage to this region of chro-
mosome 2, implying locus heterogeneity for this con-
dition (Sarfarazi et al. 1995). An additional PCG locus,
GLC3B, has been localized to chromosome 1p36 in
some families not showing linkage to the chromosome
2 markers (Akarsu et al. 1996). A subset of families not
showing linkage to either locus provided evidence for at
least a third as yet unmapped locus for this condition
(Akarsu et al. 1996). More recently, Stoilov et al. (1997)
described three different mutations in the cytochrome
P4501B1 gene, CYP1B1, in five Turkish families whose
disease previously had been linked to the 2p21 locus.
We report here that a DNA pooling strategy (Sheffield
et al. 1994) identified a PCG locus on chromosome 2 in
three consanguineous Saudi Arabian families. A poly-
morphic marker, D2S177, on chromosome 2p21 dem-
onstrated a reduction to homozygosity in the PCG-af-
fected pools and suggested that D2S177 reveals an
identity-by-descent (IBD) region that should contain
GLC3A in these families. We confirmed the localization
of GLC3A by linkage analysis in an additional 22 Saudi
Arabian families and characterized, in CYP1B1, three
point mutations as the cause of PCG in 24 of these 25
families. Our data demonstrate that 18 individuals, each
with two mutant alleles, did not show any evidence for
disease at the time of examination, suggesting reduced
penetrance for selected alleles.
Subjects, Material, and Methods
Patients
Seventy Saudi PCG families have been ascertained and
enrolled into a genetic research program, through either
the Glaucoma Clinic or the Pediatric Ophthalmology
Clinic at the King Khaled Eye Specialist Hospital
(KKESH), in Riyadh, Kingdom of Saudi Arabia. KKESH
serves as the secondary and tertiary ophthalmic insti-
tution for the entire Kingdom. The families evaluated
there are a representative set from various tribes, geo-
graphic regions, and provinces of the Kingdom. We se-
lected a panel of 25 families informative for the design
and objectives of this study. These families have been
described in detail elsewhere (Anderson et al. 1996) (fig.
1). Within each kindred, a detailed family history and
pedigree were obtained through personal interviews (by
R.A.L. and M.J.) with appropriate family members.
Each subject, or the responsible adult on behalf of mi-
nors or wards, signed a consent for participation in these
investigations, which was approved by the Baylor Af-
filiates Review Board for Human Subject Research and
by the comparable committees at KKESH. The anam-
nestic and ophthalmologic information on each individ-
ual was scored as affected or unaffected by one of three
investigators (K.F.T., W.F.A., or D.K.D.) and was re-
viewed independently by another (R.A.L.), none of
whom had prior knowledge of any linkage data. As-
signment of affected or unaffected status was based on
established criteria that include measurement of the cor-
nea and of the IOP and examination of the optic nerve
head. We carefully excluded other recognized associa-
tions or combinations of infantile glaucoma, such as
aniridia, anterior segment dysgenesis, microcornea,
Nance-Horan syndrome, Lowe syndrome, congenital
hereditary endothelial dystrophy, neurofibromatosis
type 1, and Sturge-Weber syndrome.
Controls
Fifty unrelated native Saudi Arabian adults seen at
KKESH for nonhereditary eye disease and with no fam-
ily history of hereditary eye disease served as a control
population for mutational studies of CYP1B1.
Pooling of DNA for IBD Screening
DNA was isolated from leukocytes by standard pro-
cedures (Lewis et al. 1990). Pooled samples from either
affected or unaffected individuals within selected con-
sanguineous PCG families (KKECG-122, KKECG-132,
and KKECG-146) were aliquoted into separate tubes, to
a final concentration of 8 ng/ml, for each individual in
the pooled sample (Sheffield et al. 1994). Each “af-
fected” pool consisted of DNA from three, three, and
six individuals, and each “unaffected” pool consisted of
DNA from five, four, and five individuals, fromKKECG-
122, KKECG-132, and KKECG-146, respectively.
PCR was performed (Anderson et al. 1995) in 96-well
trays in a Perkin-Elmer GeneAmp 9600 thermal cycler
for 30 cycles in 25-ml reactions containing 40–100 ng
genomic DNA, 250 nM each primer (100 nM of one
primer previously had been labeled with [32P] gATPwith
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Figure 1 Pedigrees of 25 Saudi Arabian PCG families linked to markers on chromosome 2. Affected individuals are denoted by blackened
symbols; individuals showing mild or no expression of the disease yet having haplotypes identical to those of their affected siblings are denoted
by gray-shaded symbols; deceased family members are denoted by diagonal slashes; and consanguineous matings are denoted by double lines.
Individual identification numbers are included below the symbols of affected individuals with disease chromosomes exhibiting informative
crossover events. The three families in B were used for IBD analysis. Affected and unaffected individuals used in the IBD screen are labeled
“A” and “U,” respectively.
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Table 1
Primers Used in the Amplification of CYP1B1 Coding Exons
Exon and Primer Sequence
2:
CY2a:
Forward 5′-AATTAACCCTCACTAAAGGGCGCTCCTGTCTCTGCACCCC-3′
Reverse 5′-GTAATACGACTCACTATAGGGCCGTCGCCGTAGCGCCGCGCC-3′
CY2b:
Forward 5′-AATTAACCCTCACTAAAGGGGGCTCACCTCTCGTTCGCTC-3′
Reverse 5′-GTAATACGACTCACTATAGGGCGCTGCCGCGCACCAGCAGCG-3′
CY2c:
Forward 5′-AATTAACCCTCACTAAAGGGGCCACGTGCTGAGCGAGGCG-3′
Reverse 5′-GTAATACGACTCACTATAGGGCTCAAGAACTTGTCCAGGATG-3′
CY2d:
Forward 5′-AATTAACCCTCACTAAAGGGAATTCGAGCAGCTCAACCGC-3′
Reverse 5′-GTAATACGACTCACTATAGGGCTGGAGCGAAACCCCAAACCC-3′
3:
CY3:
Forward 5′-AATTAACCCTCACTAAAGGGTCACTTGCTTTTCTCTCTCC-3′
Reverse 5′-GTAATACGACTCACTATAGGGCAATTTCAGCTTGCCTCTTGC-3′
T4 polynucleotide kinase), 10 mM Tris-HCl (pH 8.4),
40 mM NaCl, 1.5 mM MgCl2, 250 mM spermidine, 5%
dimethyl sulfoxide, 200 mM of each dNTP, and 0.25 U
AmpliTaq DNA polymerase (Perkin Elmer Cetus). Am-
plification products were size fractionated in 7% de-
naturing polyacrylamide gels (5.66 M urea and 32%
formamide), and polymorphic alleles were analyzed after
placement on Whatman paper and exposure to Amer-
sham-MP film.
DNA microsatellite markers (di-, tri-, and tetranu-
cleotides) of known chromosomal location, which were
selected on the basis of available high-resolution index
linkage maps (Matise et al. 1994; Utah Marker Devel-
opment Group 1995) and the Cooperative Human Link-
age Center Human Screening Set, version 6 (Research
Genetics) (Murray et al. 1994), were used to screen the
human genome for areas of homozygosity.Markerswere
chosen for their high degree of heterozygosity and for
their average spacing, of ∼10 cM, throughout the
genome.
Linkage Analysis
A total of 260 (186 unaffected and 74 affected) in-
dividuals in the 25 families were genotyped. Polymor-
phic alleles were scored by visual inspection (Leppert et
al. 1994). Primer sequences and reaction conditions are
available from the Genome Data Base (http://
gdbwww.gdb.org/gdb/), for the following 11 markers:
D2S1400 (GGAA20G10), D2S1360 (GATA11H10),
D2S405 (GATA8F07), D2S2383 (AFMa082xe1),
D2S352 (AFM296vg9), D2S1325 (GATA22E06),
D2S1788 (GATA86E02), D2S2186 (AFM163xc11),
D2S177 (AFM267zc9), D2S1346 (ATA21D11), and
D2S1356 (ATA4F03). Two observers (B.A.B. and
K.L.A.), each of whom was masked to affected status,
scored the genotypes independently. Two-point linkage
analyses were performed with the MLINK subroutine
of the LINKAGE program (Lathrop et al. 1985), with
an autosomal recessive mode of inheritance, a pene-
trance of .8, a disease-allele frequency of .02, and equal
marker-allele frequencies.
Sequence Analysis of CYP1B1 Coding Region
CYP1B1 (GenBank accession number U56438 [http:
//www.ncbi.nlm.nih.gov/genbank/queryform.html])
coding exons 2 and 3 were each amplified from genomic
DNA, under standard conditions (Anderson et al. 1995),
with combinations of intron-specific and exon-specific
primers tailed with 21 M13 sequences (forward re-
actions) and M13 reverse sequences (reverse reactions).
The primers are listed as table 1. PCR products were
then purified with the QIAquick PCR Purification Kit
according to the manufacturer’s recommendations. Se-
quencing reactions were performed with the ABI Prism
Dye Primer Cycle Sequencing Ready Reaction Kit, with
AmpliTaq DNA polymerase and FS with 21 M13
primers and M13 reverse primer, for the forward and
reverse reactions, respectively, as specified by the man-
ufacturer. Products of sequencing reactions were loaded
onto 5%Long Ranger gels andwere run on an Applied
Biosystems 377 Automated DNA Sequencer.
Results
IBD Screening
Pooled genomic DNA samples of affected and unaf-
fected individuals from selected pedigrees (KKECG-122,
KKECG-132, and KKECG-146) were genotyped with
highly polymorphic microsatellite markers. One hun-
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Figure 2 Pooled family samples for IBD screening. DNA from
three Saudi PCG families (KKECG-122, KKECG-132, and KKECG-
146) and from four Saudi Bardet-Biedl syndrome (BBS) families, used
as controls, are combined into affected (lanes A) and unaffected (lanes
U) pools and are used as PCR templates for the short-tandem-repeat
polymorphic marker D2S177. DNA from three unrelated individuals
(C1–C3) are also used as controls to assess individual marker “per-
sonality.” Note the shift in allele pattern to homozygosity in the PCG-
affected pools (lanes A), compared with the unaffected pools (lanes
U), the BBS pools, and the controls. The reduction to homozygosity
in the affected pools suggests that D2S177 identifies an IBD region
linked to a PCG locus in these families.
Table 2
Z Values for GLC3A and 11 Markers on 2p21 in 25 Saudi Arabian PCG Families
LOCUS
LOD SCORE AT v 
Zmax vmax.001 .01 .05 .10 .20 .30 .40
D2S1400 2.59 1.83 .51 .11 .45 .33 .11 .45 .207
D2S1360 11.77 6.14 1.67 .07 .75 .61 .24 .77 .220
D2S405 3.09 1.46 .19 .80 .87 .49 .13 .94 .153
D2S2383 5.09 1.60 1.49 2.34 2.10 1.14 .30 2.43 .129
D2S352 1.48 2.59 3.39 3.35 2.52 1.40 .44 3.43 .069
D2S1325 1.25 4.05 6.29 6.41 4.89 2.77 .94 6.50 .078
D2S1788 1.91 5.07 7.46 7.71 6.08 3.54 1.20 7.76 .084
D2S2186 8.27 9.71 10.52 9.95 7.39 4.22 1.40 10.52 .047
D2S177 15.09 15.65 15.41 13.99 9.97 5.53 1.77 15.76 .021
D2S1346 14.26 14.16 13.32 11.83 8.26 4.57 1.51 14.27 .000
D2S1356 8.03 9.34 9.84 9.09 6.52 3.62 1.20 9.88 .038
dred eighty-nine markers spanning chromosomes 1–6,
8, 11, 13, and part of 17, at ∼10-cM intervals, were
analyzed. One highly polymorphic marker on 2p21
(D2S177) showed a reduction to homozygosity in all the
PCG affected pools, when compared with the unaffected
pools, for all three families tested. These data suggested
thatD2S177 reveals an IBD region linked to the putative
PCG locus, GLC3A, in these families (fig. 2).
Genetic Analysis
Because of both the reduction to homozygosity at
D2S177 in three separate families in the IBD screen and
the report, while our screen was in progress, of a PCG
gene at the same locus (Sarfarazi et al. 1995), we geno-
typed 260 individuals from 25 PCG Saudi Arabian fam-
ilies including 74 affected individuals (fig. 1) with 11
highly polymorphic markers that map to this region (ta-
ble 2). The maximum combined two-point LOD score
(Zmax) for D2S177 and the disease locus in all families
was 15.76 at a maximum recombination fraction (vmax)
of .021 (table 2).
To determine the most likely position of GLC3A rel-
ative to the 11 linked markers, we analyzed recombi-
nants segregating with GLC3A, for the region between
D2S1325 andD2S1356, in these 25 families. Ten disease
chromosomes showed informative crossover events be-
tween the disease locus and flanking loci. These recom-
binational events narrowed theGLC3A locus to a 5-cM
interval flanked by D2S2186 and D2S1356 (table 3).
Eighteen clinically unaffected individuals in 11 fam-
ilies were noted to have haplotypes identical to those of
their affected siblings, which suggested decreased pen-
etrance for this phenotype in our cadre of Saudi families
(data not shown). The identification of these individuals
allows an accurate calculation of the penetrance in this
population ( ) and confirms our initial74/[18 74]  .8
estimate of .8. However, subsequent interviews of these
families revealed that at least two individuals who pre-
viously had been deemed unaffected but who had an
“affected” haplotype (i.e., individuals KKECG-123-06
and KKECG-151-05) were diagnosed with glaucoma a
few years after their initial enrollment in the study. Thus,
PCG shows variable expressivity in this population.
More-detailed longitudinal ophthalmologic examina-
tion of these families is characterizing further the phe-
notype of these individuals.
Mutation Analysis
Because of a report of CYP1B1 mutations in PCG
individuals (Stoilov et al. 1997), we screened the
CYP1B1 coding regions and identified three different
transition mutations that, by conceptual translation, re-
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Table 3
Summary of 10 Informative Recombinants Localizing the GLC3A Locus on 2p21
LOCUS
RECOMBINANT STATUS (PARENTAL ORIGIN OF CHROMOSOME) OFa
104-04 (M) 108-08 (P) 122-05 (M) 123-11 (M) 129-27 (M) 135-06 (M) 140-06 (M) 146-03 (P) 146-04 (M) 157-04 (P)
D2S1325 R ) N N N R N ) ) R
D2S1788 ) ) R N R N R ) ) )
D2S2186 ) ) ) R ) ) ) ) ) )
D2S177 ) ) ) ) ) ) ) ) ) )
D2S1346 ) N ) ) ) ) ) N N )
D2S1356 ) R ) ) ) ) ) R R )
a P  paternal; M  maternal; R  recombinant; N  not informative; and an ellipsis ())  nonrecombinant.
Table 4
Summary of Mutations in Affected Members of 24 Saudi
Arabian Families
Family/
Families
(KKECG
Number) Mutation in Exon 2 Mutations in Exon 3
35, 104,
107, 113,
116, 122
123, 125,
129, 132,
135, 137
139, 140,
148, 154,
157
3987GrA (G61E)a Wild type
114, 151 3987GrA (G61E) 7957GrA (D374N)
150 3987GrA (G61E) 8242CrT (R469W)
108, 112,
170
Wild type 8242CrT (R469W)a
146 Wild type 7957GrA (D374N)a
a Homozygous.
sult in missense amino acid substitution in 24 of the 25
families, which are summarized in table 4. The mutant
alleles cosegregate with the disease phenotype in each
family. As anticipated, in most families the affected in-
dividuals were homozygous for the mutant allele. Care-
ful analysis of the haplotypes did not show conclusive
evidence either for or against a founder effect for each
of the three mutations (data not shown). However, af-
fected individuals in families KKECG-114, KKECG-
150, and KKECG-151 were compound heterozygotes.
We also confirmed our initial finding of variable ex-
pressivity of the phenotype, by sequencing all the clin-
ically unaffected individuals who had haplotypes iden-
tical to those of their affected siblings. All 18 individuals
were either homozygous or compound heterozygous for
mutations in CYP1B1, with no apparent correlation
with the type of mutation. Interestingly, four fami-
lies (KKECG-137, KKECG-146, KKECG-148, and
KKECG-154) demonstrated a pseudodominant pattern
of segregation (fig. 3). Direct sequence analysis (fig. 4)
confirmed both the segregation of the mutant alleles and
the molecular bases for the pseudodominant transmis-
sion. Sequence analysis of the CYP1B1 coding region in
50 randomly sampled Saudi controls (100 chromo-
somes) with no known inherited eye disease showed
none of these three mutations (data not shown).
Discussion
Both genetic linkage to markers on 2p21 and evidence
for genetic heterogeneity have been reported in Turkish
PCG families (Sarfarazi et al. 1995). Additionally, three
different mutations in CYP1B1 have been described in
five Turkish families, suggesting a potential role for
CYP1B1 in ocular development. These three were ho-
mozygous frameshift mutations: a 13-bp deletion in
exon 3; an insertion of a single cytosine base in exon 2;
and a larger deletion affecting the 5′ end of exon 3 and
adjacent intronic sequences. Each of these mutations
may result in a functionally null allele (Stoilov et al.
1997).
Our screen of the human genome for regions of IBD
by means of a DNA pooling strategy in three consan-
guineous Saudi Arabian PCG pedigrees identified on
2p21 a locus where a reduction to homozygosity in af-
fected individuals was observed. These data suggested
that this locus is linked to a putative PCG gene in these
Saudi families. The presence of a PCG gene at this locus
was then confirmed by formal linkage analysis in 25
Saudi Arabian families.We found no evidence for genetic
heterogeneity in this population. Our data suggest var-
iable expressivity for the PCG phenotype in the Saudi
population, since 18 apparently unaffected individuals
have haplotypes identical to those of their affected sib-
lings; two of these individuals (KKECG-123-06 and
KKECG-151-05) were subsequently diagnosed with
glaucoma. Mutation analysis of the coding exons of
CYP1B1 in the 25 families showed either homozygous
or compound heterozygous mutations in every affected
individual investigated ( ) in 24 of these families.N  30
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Figure 3 Pedigrees of the four families (KKECG-137, KKECG-146, KKECG-148, KKECG-154), showing pseudodominant inheritance of
the PCG phenotype. The homozygous mutations that segregate with the disease phenotype are shown under the affected individuals (pedigree
symbols as in fig. 1).
In each family, the mutant alleles cosegregate with the
disease phenotype in an autosomal recessive pattern. In-
triguingly, four highly consanguineous families show
pseudodominant transmission of the phenotype. This
finding is likely due to both the presence of multiple
consanguinity loops and a high frequency of mutant al-
leles in this population. Sequence analysis of the affected
parents showed homozygous mutations in bothCYP1B1
alleles, thus supporting the molecular basis for this clin-
ical observation (fig. 3).
Three distinctive missense mutations that appear to
correlate with tribal ancestry were defined in 24 Saudi
Arabian families. The most common mutation, a GrA
transition at nucleotide 3987, occurs in 78% of the PCG
chromosomes analyzed and results in a missense amino
acid substitution of glycine by glutamic acid, at position
61, adjacent to the N-terminal proline-rich region of
CYP1B1. The proline-proline-glycine-proline motif may
serve to join the membrane-binding N-terminus to the
globular region of the P450 protein (Gonzalez 1989).
The second mutation, a CrT transition at nucleotide
8242, occurs in 10% of the PCG chromosomes and
changes arginine to tryptophan at position 469 of the
protein. This switch from a basic to an aromatic amino
acid, adjacent to a highly conserved cysteine residue (po-
sition 470) observed from bacteria to human (Gonzalez
1989), would be expected to alter substantially the pu-
tative enzymatic function of CYP1B1. The third muta-
tion, a GrA transition at nucleotide 7957, in 6% of the
PCG chromosomes, results in a change of aspartic acid
to asparagine, at position 374 of the protein. All three
mutated amino acid residues are highly conserved
among different species and across the entire P450
superfamily (http://dot.imgen.bcm.tmc.edu:9331/seq-
search/Help/beautypp.html).
The three mutations described in the five Turkish fam-
ilies are presumed to result in null alleles (Stoilov et al.
1997). In contrast, the three mutations identified in our
panel of 24 Saudi families do not cause a shift in the
reading frame of the gene and are likely to alter the
putative enzymatic function of the protein. These may
represent hypomorphic alleles whose phenotypic con-
sequences could potentially be altered by levels of ex-
pression, modifier genes, or other factors, thus resulting
in decreased penetrance and variability of expression.
CYP1B1 is a dioxin-inducible member of the cyto-
chrome P450 gene superfamily (Sutter et al. 1991, 1994;
Tang et al. 1996) and has a yet-undefined role in ocular
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Figure 4 Three missense mutations observed in CYP1B1 in 24
Saudi families. Direct sequencing of PCR products in homozygous and
heterozygous individuals is shown, to demonstrate the segregation of
the mutations with disease phenotype. One nuclear family each from
KKECG-113, KKECG-108, and KKECG-146 is shown, with the cor-
responding electropherogram. The nucleotide sequence is N  G/A
for KKECG-113, N  C/T for KKECG-108, and N  G/A for
KKECG-146.
development. CYP1B1 and other drug-metabolizing en-
zymes seem to regulate the steady state of ligands that
affect growth and differentiation (Nebert 1990, 1991).
Mutations that alter the function of CYP1B1 presum-
ably disrupt that steady state and result in either ab-
normally high levels of these ligands or prolonged ex-
posure of the developing tissues to these postulated
effectors of growth and development. Either event could
potentially cause structural aberrations in the developing
tissues.
Future studies of CYP1B1, as well as the identification
of its putative ligands, will contribute to the understand-
ing of both ocular development and the role of other
drug-metabolizing enzymes in organogenesis. Further
detailed clinical and molecular examinations of the
mildly affected patients described here, as well as of their
environmental exposures, may identify additional fac-
tors that influence the expression of the PCG phenotype.
Such knowledge should provide pharmacological targets
for the antenatal modulation or postnatal therapy of
PCG and, possibly, other forms of glaucoma. Finally,
that only three distinctive mutations are responsible for
94% of the PCGmutations in the Saudi Arabian families
that we examined suggests that neonatal or population
screening for early therapeutic intervention would be an
attractive public health approach to decrease the burden
of infantile glaucoma in this population.
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